Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Harrow
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
May 17, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
May 04, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
May 02, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
April 27, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
March 28, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
March 23, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
March 13, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
March 06, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
March 02, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Launches Next-Generation Compounded Atropine Formulations
February 15, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
February 02, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
January 23, 2023
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Prices $25 Million Offering
December 14, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
December 14, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow and iOR Partners Expand National Product Supply Agreement
November 30, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Announces Third Quarter 2022 Financial Results
November 14, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Launches Atropine.com
November 10, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
October 28, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Sells Non-Ophthalmic Compounding Business
October 05, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
September 29, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
September 27, 2022
From
Harrow
Via
Business Wire
Tickers
HROW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.